Clinical Trials
24 trialsNCT03474107 2026-01-09
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Phase 3 Completed
NCT04527991 2025-08-03
TROPiCS-04
Gilead Sciences
Phase 3 Completed
NCT01095003 2022-04-28
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT00545766 2021-12-16
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02256436 2021-09-20
MK-3475-045
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02057913 2020-07-23
VinCaP
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT01091168 2019-09-16
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT02302807 2019-08-01
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche
Phase 3 Completed
NCT01953003 2019-05-02
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT01844947 2019-04-26
VINSOR
Karolinska University Hospital
Phase 1 Completed
NCT01529411 2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02347332 2019-03-05
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT00362830 2016-09-19
A Study of the Alternative Administration of Ixabepilone and Vinflunine
Bristol-Myers Squibb
Phase 1 Completed
NCT00388557 2016-09-19
Effect of Ketoconazole on the Pharmacokinetics of Vinflunine
Bristol-Myers Squibb
Phase 1 Completed
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00284180 2013-08-09
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00284154 2013-03-13
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01265940 2012-10-10
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Lukas-Krankenhaus GmbH
Phase 1/2 Completed
NCT00320073 2012-05-16
Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00251446 2012-05-11
A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer
Veeda Oncology
Phase 2 Completed
NCT00101608 2010-03-02
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Bristol-Myers Squibb
Phase 2 Completed
NCT00315237 2010-01-07
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
Bristol-Myers Squibb
Phase 3 Completed